Skip to main content

Table 3 Summary of SSSA between-treatment comparisons (mITT population)

From: Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

  Day 3 Day 3 Day 4 Day 4 Day 8
  Hour 0 Hour 3 Hour 0 Hour 3  
Congestion      
Mucus p < 0.10   p < 0.10   p < 0.10
Cough    p < 0.05   
  1. SSSA: Spontaneous Symptom Severity Assessment; mITT: modified intent-to-treat. p < 0.05: statistically significant difference between treatment groups; p < 0.10: viewed as a trend towards a significant difference between treatment groups. Note: p-values are from Wilcoxon rank sum tests comparing treatments. Results for Hour 0 on Days 3 and 4 and for Day 8 are treatment comparisons based on within-subject changes from Baseline (Day 1). Results for Hour 3 on Days 3 and 4 are treatment comparisons based on within-subject changes from Hour 0 of the same day.